Basale insulineanalogen: voordeel bij type 2 diabetes

Slides:

Advertisements

Similar presentations

Weng TC, et al. J Clin Pharm Ther 2010;35:

Advertisements

New Insulin Formulations Guillermo Umpierrez, MD, FACP, FACE Professor of Medicine Emory University School of Medicine Part 1.

Insulin Initiation In Primary Care Dr Arla Ogilvie Endocrinologist Watford General Hospital West Herts Hospitals NHS Trust.

Should we be using the new insulins in T2DM? Ian Gallen MD FRCP Community Diabetologist Royal Berkshire Hospital.

Tamas Ungar, MD; Mayur Rali, MD FAAFP

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Life expectancy at birth in all countries included

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Identification of mucinous carcinoma

Figure 5 Risk factor control in the intensive treatment group

Figure 2 Examples of histopathological validation

Sweetened Drinks and Risk of Diabetes

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Figure 1 Health-care system today

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Example: If line AB is parallel to line CD and s is parallel to t, find the measure of all the angles when m< 1 = 100°. Justify your answers. t

Depicted are patient and disease factors used to determine optimal A1C targets. Depicted are patient and disease factors used to determine optimal A1C.

Figure 2 Median monthly launch price of a new anticancer drug,

Flowchart of literature search for the effect of fructose on glycemic end points (fasting glucose, fasting insulin, and glycated blood proteins [HbA1c.

Nat. Rev. Endocrinol. doi: /nrendo

Jacques Irani European Urology Supplements

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Nat. Rev. Urol. doi: /nrurol

Impact of U-100 RHI administered with V-Go at OV1 (3 months after initiation) and OV2 (6 months after initiation) (n = 11) at 3 months (P = 0.32) and at.

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Figure 3 Pharmacodynamic action profiles of long-acting insulins

Patient flow chart: the final prospective study population consisted of 521 individuals, 113 on basal insulin and 408 on OADs. *Plausibility: height (130–230 cm),

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Frequency of lesions detected using CNS imaging (computed tomography [CT] and magnetic resonance imaging [MRI]) on patients with baylisascariasis (see.

Figure 5 Schematic overview of a clinical decision-support

Kaplan-Meier plot of incident CVD according to the treatment group over a 4-year period following intensification of diabetes therapy. Kaplan-Meier plot.

Nat. Rev. Cardiol. doi: /nrcardio

Receiver operating characteristic analyses showing area under the curves with reference to 2-hour OGTT (A,B) and fasting plasma glucose (C,D). HbA1c, glycated.

A) Healthcare utilisation, b) short form (SF)-12 scores and c) work productivity and activity impairment in patients with asthma (▓) and diabetes (▪) in.

Figure 4 Radiogenomics analysis can reveal relationships

Approximate numbers of cases per 100,000 individuals caused by penicillin resistance for each year (left). Approximate numbers of cases per 100,000 individuals.

Inclusion process. Inclusion process. Of 5200 eligible patients, 204 declined participation, 111 had diabetes >400 days before All New Diabetics in Scania.

Association between antibiotic purchases and glycated hemoglobin (HbA1c) values in patients with and without diabetic nephropathy. Association between.

Relationships between annual antibiotic purchase rates and progression of microalbuminuria in patients with type 1 diabetes. Relationships between annual.

Figure 3 Determination of the primary site

When queried about the supply of endocrinologists to manage diabetes, respondents felt that there are not enough endocrinologists. When queried about the.

Serial measurements of serum glucose, anion gap, serum carbon dioxide, and serum triglycerides throughout the patient's hospital stay. Serial measurements.

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

Increasing prevalence of multidrug resistance among P

Flow chart of patients who met inclusion/exclusion criteria in the identified study population.1 Excluded because they were living in nursing facility.

A and B: Flow cytometric analysis of the effect of MRP-8/14 in the serum of a type 1 diabetic patient on the surface expression of CD11b and CD118. A and.

Number of outbreaks associated with drinking water by water system type and year (n = 780), 1971 to “Other” includes outbreaks associated with bottled.

Percentages of outbreak deficiencies (n = 671) in public water systems (n = 656) by time period, 1971 to 2006, excluding outbreaks associated with Legionella.

The possible off-target effect of increased heart failure hospitalizations from saxagliptin in the SAVOR trial. The possible off-target effect of increased.

Effect of 4 weeks of an intensive exercise program on vaspin serum concentrations in normal glucose tolerant (NGT) individuals and patients with IGT or.

This figure illustrates the importance of heart failure consideration in primary endpoint trials with hypoglycemic agents. This figure illustrates the.

Percentages of 256 clinical isolates obtained from immunocompetent and immunocompromised patients (HIV positive) and from patients with other risk factors.

Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.

Hector H. García et al. Clin. Microbiol. Rev. 2002; doi: /CMR

HbA1c differences between intensively and conventionally treated patients in major clinical trials, with baseline to endpoint HbA1c level in type 1 diabetes.

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Noncontrast computed tomography of patient C. B

Roberta B. Carey et al. Clin. Microbiol. Rev. 2018; doi: /CMR

A: Probability of retinopathy-free survival.

Giemsa-stained thin blood smears from a nonobese diabetic (NOD)-SCID mouse infected with (A) B. microtistrain MN1, (B) a hamster infected with B. microti.

New dialysis starts in the United States by year in patients with and without diagnosis of diabetes. New dialysis starts in the United States by year in.

Mean HbA1c (%) and estimated marginal mean SH rate (per 100 patient-years) adjusted for sex, age-group at diagnosis, and diabetes duration, by time period,

Fresh perspectives ON BASAL Insulins in diabetes care

(A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects. (A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects.

Presentation transcript:

Basale insulineanalogen: voordeel bij type 2 diabetes HbA1c gelijk, minder hypo (RR=0.66 – 0.84) The discussion is soon narrowed to the level of evidence based medicine, and from that angle the only advantage of long-acting analogues is the reduced incidence of hypo they carry. Hypo: 3.6 confirmed. 0.5 hypo per patient year less, does that justify twice the price? So minor advantages, but does evidence base capture everything? Horvath et al. Cochrane System Rev 2007 Apr 18;(2):CD005613 Mullins et al. Clin Ther 2007; 1607 1